Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Suresh Senan

Showing results (281-290 of 348) with videos related to

Pageof 35
Sort By:
The Lancet Regional Health. Europe|March 13, 2024
New systemic treatment paradigms in resectable non-small cell lung cancer and variations in patient access across EuropeIlias Houda, Chris Dickhoff, Carin A Uyl-de Groot, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|April 29, 2025
Metastasectomy versus stereotactic body radiotherapy for patients with oligometastatic colorectal lung metastases: a systematic reviewSimone A Gooijer, Anna S M Gazendam, Bart Torensma, et al.
Cancers|September 30, 2020
The Role of Daily Adaptive Stereotactic MR-Guided Radiotherapy for Renal Cell CancerShyama U Tetar, Omar Bohoudi, Suresh Senan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 3, 2018
Differences in Longitudinal Health Utility between Stereotactic Body Radiation Therapy and Surgery in Stage I Non-Small Cell Lung CancerHenri B Wolff, Leonie Alberts, Elisabeth A Kastelijn, et al.
BMC Cancer|July 25, 2012
Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): study protocol for a randomized phase II trialDavid A Palma, Cornelis J A Haasbeek, George B Rodrigues, et al.
Acta Oncologica (Stockholm, Sweden)|March 31, 2017
Optimizing SABR delivery for synchronous multiple lung tumors using volumetric-modulated arc therapyHilâl Tekatli, Shyama U Tetar, Timothy K Nguyen, et al.
Radiation Oncology (London, England)|October 8, 2016
Salvage surgery for local failures after stereotactic ablative radiotherapy for early stage non-small cell lung cancerNaomi E Verstegen, Alexander P W M Maat, Frank J Lagerwaard, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 24, 2015
Patient reported outcomes following stereotactic ablative radiotherapy or surgery for stage IA non-small-cell lung cancer: Results from the ROSEL multicenter randomized trialAlexander V Louie, Erik van Werkhoven, Hanbo Chen, et al.
Practical Radiation Oncology|January 3, 2018
Optimal imaging surveillance after stereotactic ablative radiation therapy for early-stage non-small cell lung cancer: Findings of an International Delphi Consensus StudyTimothy K Nguyen, Suresh Senan, Jeffery D Bradley, et al.
Journal for Immunotherapy of Cancer|November 28, 2025
Immune-modulating effects on tumor-draining lymph nodes of neoadjuvant chemoradiotherapy combined with dual immunotherapy in patients with T3-4N0-2 NSCLCEzgi B Ulas, Sofie J I Koomen, Anne Vrijmoet, et al.
Pageof 35

Showing results (281-290 of 348) with videos related to

Sort By:
Pageof 35
The Lancet Regional Health. Europe|March 13, 2024
New systemic treatment paradigms in resectable non-small cell lung cancer and variations in patient access across EuropeIlias Houda, Chris Dickhoff, Carin A Uyl-de Groot, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|April 29, 2025
Metastasectomy versus stereotactic body radiotherapy for patients with oligometastatic colorectal lung metastases: a systematic reviewSimone A Gooijer, Anna S M Gazendam, Bart Torensma, et al.
Cancers|September 30, 2020
The Role of Daily Adaptive Stereotactic MR-Guided Radiotherapy for Renal Cell CancerShyama U Tetar, Omar Bohoudi, Suresh Senan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 3, 2018
Differences in Longitudinal Health Utility between Stereotactic Body Radiation Therapy and Surgery in Stage I Non-Small Cell Lung CancerHenri B Wolff, Leonie Alberts, Elisabeth A Kastelijn, et al.
BMC Cancer|July 25, 2012
Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): study protocol for a randomized phase II trialDavid A Palma, Cornelis J A Haasbeek, George B Rodrigues, et al.
Acta Oncologica (Stockholm, Sweden)|March 31, 2017
Optimizing SABR delivery for synchronous multiple lung tumors using volumetric-modulated arc therapyHilâl Tekatli, Shyama U Tetar, Timothy K Nguyen, et al.
Radiation Oncology (London, England)|October 8, 2016
Salvage surgery for local failures after stereotactic ablative radiotherapy for early stage non-small cell lung cancerNaomi E Verstegen, Alexander P W M Maat, Frank J Lagerwaard, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 24, 2015
Patient reported outcomes following stereotactic ablative radiotherapy or surgery for stage IA non-small-cell lung cancer: Results from the ROSEL multicenter randomized trialAlexander V Louie, Erik van Werkhoven, Hanbo Chen, et al.
Practical Radiation Oncology|January 3, 2018
Optimal imaging surveillance after stereotactic ablative radiation therapy for early-stage non-small cell lung cancer: Findings of an International Delphi Consensus StudyTimothy K Nguyen, Suresh Senan, Jeffery D Bradley, et al.
Journal for Immunotherapy of Cancer|November 28, 2025
Immune-modulating effects on tumor-draining lymph nodes of neoadjuvant chemoradiotherapy combined with dual immunotherapy in patients with T3-4N0-2 NSCLCEzgi B Ulas, Sofie J I Koomen, Anne Vrijmoet, et al.
Pageof 35